0001104659-24-007066.txt : 20240126
0001104659-24-007066.hdr.sgml : 20240126
20240126113320
ACCESSION NUMBER: 0001104659-24-007066
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240124
FILED AS OF DATE: 20240126
DATE AS OF CHANGE: 20240126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lisicki Robert
CENTRAL INDEX KEY: 0001779614
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40598
FILM NUMBER: 24565514
MAIL ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zura Bio Ltd
CENTRAL INDEX KEY: 0001855644
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4225 EXECUTIVE SQUARE
STREET 2: SUITE 600
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-247-0520
MAIL ADDRESS:
STREET 1: 4225 EXECUTIVE SQUARE
STREET 2: SUITE 600
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: JATT Acquisition Corp
DATE OF NAME CHANGE: 20210407
4
1
tm244212-4_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-24
0
0001855644
Zura Bio Ltd
ZURA
0001779614
Lisicki Robert
C/O ZURA BIO LIMITED
1489 W. WARM SPRINGS RD. #110
HENDERSON
NV
89014
0
1
0
0
See Remarks
0
Stock options
3.98
2024-01-24
4
A
0
1000000
0
A
2034-01-24
Class A Ordinary Shares
1000000
1000000
D
Consists of options to purchase 1,000,000 Class A Ordinary Shares. The vesting for 600,000 of 1,000,000 shares began on January 8, 2024 and would vest over a period of four years, with 1/4 to be vested on 01/08/2025, and thereafter 1/48 on a monthly basis. The vesting for 400,000 of 1,000,000 shares shall begin on the date of Mr. Lisicki's promotion and shall vest over a period of four years, with 1/4 to be vested on the first anniversary of the promotion date, and thereafter 1/48 on a monthly basis.
President, Chief Operating Officer
/s/ Robert Lisicki
2024-01-26